Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)

Blood (2013) 122 (21): 2.

https://doi.org/10.1182/blood.V122.21.2.2

Published: 2013

Journal Articles

Pomalidomide In Sickle Cell Disease: Phase I Study Of a Novel Anti-Switching Agent

Abdullah Kutlar, MD, Paul S. Swerdlow, MD, Steffen E. Meiler, MD, Kavita Natrajan, MBBS, Leigh G Wells, MSN, RN, FNP-BC, Betsy Clair, Sheetal Shah, BA, Robert Knight, MD

Blood (2013) 122 (21): 777.

https://doi.org/10.1182/blood.V122.21.777.777

Published: 2013

Journal Articles

Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.

Guntram Buesche, MD, Aristoteles Giagounidis, MD, Gudrun Göhring, Brigitte Schlegelberger, Stephanie Dieck, Robert Knight, MD, Carlo Aul, MD, Hans H. Kreipe, MD

Blood (2012) 120 (21): 2826.

https://doi.org/10.1182/blood.V120.21.2826.2826

Published: 2012

Journal Articles

Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,

Guntram Buesche, M.D., Aristoteles Giagounidis, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, M.D., Stephanie Dieck, Robert Knight, MD, Carlo Aul, MD, Hans H. Kreipe, MD

Blood (2011) 118 (21): 3819.

https://doi.org/10.1182/blood.V118.21.3819.3819

Published: 2011

Journal Articles

Safety, Efficacy, and Quality-of-Life Study of Lenalidomide Plus Dexamethasone In Previously Treated Patients with Multiple Myeloma: The Spanish Experience

Adrian Alegre, Albert Oriol-Rocafiguera, Jose García-Laraña, María-Victoria Mateos, Anna Sureda, MD, PhD, Carmen Martínez Chamorro, María Teresa Cibeira, MD, PhD, Robert Knight, MD, Barbara Rosettani

Blood (2010) 116 (21): 3045.

https://doi.org/10.1182/blood.V116.21.3045.3045

Published: 2010

Journal Articles

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Aleksandr Lazaryan, MD, MPH, PhD, Rachid Baz, MD, Mohamad A Hussein, Jr, MD, Paul Elson, ScD, Beth Faiman, CNP, Becky Habecker, Mary Ann Karam, RN, Janice Reed, RN, Kimberly Hamilton, RN, Kellie Bruening, Gordan Srkalovic, MD, PhD, Steven Andresen, DO, Matt Kalaycio, MD, John William Sweetenham, MD, FRCP, Ronald Sobecks, MD, Robert Dean, MD, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Frederic J. Reu, MD

Blood (2010) 116 (21): 1967.

https://doi.org/10.1182/blood.V116.21.1967.1967

Published: 2010

Journal Articles

Peripheral Neuropathy In Multiple Myeloma Patients Treated with Lenalidomide

Carmen Castaneda, Lilia Weiss, Neil A. Minton, MD, MRCP, Alex Kim, John Freeman, Zhinuan Yu, Robert Knight, MD

Blood (2010) 116 (21): 5024.

https://doi.org/10.1182/blood.V116.21.5024.5024

Published: 2010

Journal Articles

Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality.

Guntram Buesche, MD, Stephanie Dieck, Aristoteles Giagounidis, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Robert Knight, MD, Carlo Aul, MD, Hans Kreipe, MD

Blood (2009) 114 (22): 3800.

https://doi.org/10.1182/blood.V114.22.3800.3800

Published: 2009

Journal Articles

RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004).

Pierre Fenaux, Aristotle Giagounidis, Dominik Selleslag, MD, Odile Beyne-Rauzy, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Moshe Mittelman, MD, Petra Muus, MD, PhD, Peter te Boekhorst, MD, PhD, Guillermo Sanz, MD, PhD, Consuelo del Cañizo, Agnes Guerci-Bresler, Brigitte Schlegelberger, M.D., Carlo Aul, Hans Kreipe, MD, Gudrun Goehring, Robert Knight, MD, John Francis, Tommy Fu, Eva Hellstrom-Lindberg, MD, PhD

Blood (2009) 114 (22): 944.

https://doi.org/10.1182/blood.V114.22.944.944

Published: 2009

Journal Articles

ACE-011, a Soluble Activin Receptor Type Iia IgG-Fc Fusion Protein, Increases Hemoglobin (Hb) and Improves Bone Lesions in Multiple Myeloma Patients Receiving Myelosuppressive Chemotherapy: Preliminary Analysis.

Kudrat M. Abdulkadyrov, M.D., Ph.D., Galina N. Salogub, M.D., Ph.D., Nuriet K. Khuazheva, M.D., Ph.D., Rachel Woolf, Eric Haltom, Niels G. Borgstein, MD, Robert Knight, MD, Gary Renshaw, DO, Yijun Yang, Matthew L. Sherman, MD

Blood (2009) 114 (22): 749.

https://doi.org/10.1182/blood.V114.22.749.749

Published: 2009

Journal Articles

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Luhua Wang, MD, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Barry Samuels, MD, Qing Yi, MD, PhD, Barbara Pro, MD, Michelle Fanale, M.D., Jatin Shah, MD, Anas Younes, MD, Neda Bell, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Fernando Cabanillas, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 2719.

https://doi.org/10.1182/blood.V114.22.2719.2719

Published: 2009

Journal Articles

Overview of Venous Thromboembolism (VTE) in Nearly 100,000 Patients Treated with Revlimid® (lenalidomide).

Lilia Weiss, MD, Kamal Shah, MD, Wai Yiu, PharmD, John Freeman, MSc., BSc., LLB, DipClinSci., Robert Knight, MD, Jerome B. Zeldis, MD

Blood (2009) 114 (22): 2881.

https://doi.org/10.1182/blood.V114.22.2881.2881

Published: 2009

Journal Articles

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Michael Wang, MD, Luis Fayad, MD, Frederick Hagemeister, MD, Sattva Neelapu, MD, Barry Samuels, MD, Felipe Samanigo, MD, Barbara Pro, MD, Qing Yi, MD, PhD, Neda Bell, Catriona Byrne, Pam Weaver, Kim Hartig, Robert Knight, MD, Jerry Zeldis, MD, Larry Kwak, MD, PhD, Jorge Romaguera, MD

Blood (2007) 110 (11): 2562.

https://doi.org/10.1182/blood.V110.11.2562.2562

Published: 2007

Journal Articles

Two-Stage Pharmacokinetic & Efficacy Study of Lenalidomide Alone or Combined with Recombinant Erythropoietin (EPO) in Lower Risk MDS EPO-Failures [PK-002].

Alan F. List, MD, Jeffrey E. Lancet, MD, Magda Melchert, MD, Hussein Saba, MD, Richard Lush, PhD, Jian Yu, PhD, Nianhang Chen, PhD, Michele Schmidt, RN, Robert Knight, MD

Blood (2007) 110 (11): 4626.

https://doi.org/10.1182/blood.V110.11.4626.4626

Published: 2007

Journal Articles

Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.

Edward Stadtmauer, MD, Donna Weber, MD, M. Dimopolous, MD, Andrew Belch, MD, Michel Attal, MD, Miles Prince, MD, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, MD, Robert Knight, MD

Blood (2006) 108 (11): 3552.

https://doi.org/10.1182/blood.V108.11.3552.3552

Published: 2006

Journal Articles

Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.

Michael Wang, MD, Robert Knight, MD, Melitios Dimopoulos, MD, David Siegel, MD, S. Vincent Rajkumar, MD, Thierry Facon, MD, Raymond Alexanian, MD, Zhinuan Yu, PhD, Jerome Zeldis, MD, PhD, Marta Olesnyckyj, Donna Weber, MD

Blood (2006) 108 (11): 3553.

https://doi.org/10.1182/blood.V108.11.3553.3553

Published: 2006

Journal Articles

Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.

Asher Alban Chanan-Khan, MD, Zhinuan Yu, PhD, Donna Weber, MD, Christine Chen, MD, Ruben Niesvizky, MD, Andrew Spencer, MD, Michel Attal, MD, Andrew Belch, MD, Miles Prince, MD, Marta Olesnyckyj, Robert Knight, MD, Jerome Zeldis, MD, Meletius Dimopoulos, MD

Blood (2006) 108 (11): 3554.

https://doi.org/10.1182/blood.V108.11.3554.3554

Published: 2006

Journal Articles

N-ras m -Transduced Fibroblasts Facilitate the Expansion and Engraftment of Umbilical Cord Blood Stem Cells.

Alla Dolnikov, PhD, Tiffany Holmes, MSc, Sylvie Shen, PhD, Robert Knight, MD, Tracey A. O’Brien, MBChB, FRACP, MHL, BSc

Blood (2006) 108 (11): 3196.

https://doi.org/10.1182/blood.V108.11.3196.3196

Published: 2006

Journal Articles

Use of Lenalidomide (Revlimid® +/− Corticosteroids in Relapsed/Refractory Multiple Myeloma Patients with Elevated Baseline Serum Creatinine Levels.

Donna E. Reece, MD, Esther Masih-Khan, PhD, Christine Chen, MD, Lisa Wang, Saima Dean, Vishal Kukreti, MD, Joseph R. Mikhael, MD, Suzanne Trudel, MD, Robert Knight, MD, Jerome Zeldis, MD

Blood (2006) 108 (11): 3548.

https://doi.org/10.1182/blood.V108.11.3548.3548

Published: 2006

Journal Articles

Lenalidomide (Revlimid®) +/− Corticosteroids in Elderly Patients with Relapsed/Refractory Multiple Myeloma.

Donna E. Reece, MD, Esther Masih-Khan, PhD, Christine Chen, MD, Lisa Wang, Saima Dean, Suzanne Trudel, MD, Joseph R. Mikhael, MD, Vishal Kukreti, MD, Robert Knight, MD, Jerome Zeldis, MD

Blood (2006) 108 (11): 3550.

https://doi.org/10.1182/blood.V108.11.3550.3550

Published: 2006

NARROW

Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)

Pomalidomide In Sickle Cell Disease: Phase I Study Of a Novel Anti-Switching Agent

Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.

Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,

Safety, Efficacy, and Quality-of-Life Study of Lenalidomide Plus Dexamethasone In Previously Treated Patients with Multiple Myeloma: The Spanish Experience

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Peripheral Neuropathy In Multiple Myeloma Patients Treated with Lenalidomide

Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality.

RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004).

ACE-011, a Soluble Activin Receptor Type Iia IgG-Fc Fusion Protein, Increases Hemoglobin (Hb) and Improves Bone Lesions in Multiple Myeloma Patients Receiving Myelosuppressive Chemotherapy: Preliminary Analysis.

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Overview of Venous Thromboembolism (VTE) in Nearly 100,000 Patients Treated with Revlimid® (lenalidomide).

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Two-Stage Pharmacokinetic & Efficacy Study of Lenalidomide Alone or Combined with Recombinant Erythropoietin (EPO) in Lower Risk MDS EPO-Failures [PK-002].

Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.

Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.

Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.

N-ras m -Transduced Fibroblasts Facilitate the Expansion and Engraftment of Umbilical Cord Blood Stem Cells.

Use of Lenalidomide (Revlimid® +/− Corticosteroids in Relapsed/Refractory Multiple Myeloma Patients with Elevated Baseline Serum Creatinine Levels.

Lenalidomide (Revlimid®) +/− Corticosteroids in Elderly Patients with Relapsed/Refractory Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only